Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 10 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- The INFLUENCE of Cytoreduction on PRO in EOCActive, not recruitingNCT03268876
- Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian CancerStatus unknownNCT03235648Not applicable
- Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCACompletedNCT03229122
- Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial CancerStatus unknownNCT03220932Phase 3
- Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® TechnologyStatus unknownNCT03219242Not applicable
- Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal IntCompletedNCT03213964Phase 1
- Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant ChemotherapyCompletedNCT03206645Phase 1
- China Ovarian Cancer BRCA Testing StudyTerminatedNCT03203993
- Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer SurvivorsCompletedNCT03198286Not applicable
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian CancerStatus unknownNCT03188159Phase 2
- Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerStatus unknownNCT03180177Phase 3
- Phase Ib Study of Chiauranib in Patients With Ovarian CancerCompletedNCT03166891Phase 1/2
- The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian CancerTerminatedNCT03162562Phase 1
- Resistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinCompletedNCT03161132Phase 2
- Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.CompletedNCT03155451
- EDMONd - Elemental Diet in Bowel ObstructionStatus unknownNCT03150992Not applicable
- Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageStatus unknownNCT03150121Not applicable
- Perioperative Early Tiredness (Acute Fatigue) in Patients With Epithelial Ovarian CancerCompletedNCT03131102
- Long Term Survivors in Ovarian CancerTerminatedNCT03128294
- Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerCompletedNCT03126812Phase 1/2
- Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype FamiliesCompletedNCT03119285
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
- Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal OriginTerminatedNCT03100006Phase 1/2
- Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf RegionCompletedNCT03082976
- A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian CancerCompletedNCT03081702Phase 1/2
- Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.Approved for marketingNCT03079687
- Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian CancerStatus unknownNCT03078400Phase 1
- Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian CancerCompletedNCT03075540Not applicable
- A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
- A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian CancerCompletedNCT03069872Not applicable
- Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in JapanNo longer availableNCT03063710
- Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1
- Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian CancerCompletedNCT03055143Phase 1
- Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian CancerCompletedNCT03028519Early Phase 1
- Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerApproved for marketingNCT03025867
- The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer PatientsStatus unknownNCT03019315
- Inherited Susceptible Genes Among Epithelial Ovarian CancerStatus unknownNCT03015376
- An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing SurgeryCompletedNCT03011320Phase 1
- Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125CompletedNCT03004391
- Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in FranceStatus unknownNCT02981901
- Determinants of Age-Related Treatment Effectiveness in Ovarian CancerCompletedNCT02973750
- BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian CancerCompletedNCT02963688
- Ovarian Tumor Biopsies to Study Response to TreatmentsCompletedNCT02952521
- Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedNCT02948075Phase 2
- HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell CarcinomaTerminatedNCT02947152Phase 1
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian CarcinomaTerminatedNCT02933073Phase 1
- Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyCompletedNCT02928549
- Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision MakingCompletedNCT02916875
- Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer.CompletedNCT02910622
- ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabCompletedNCT02891824Phase 3
- Study of Predictive Factors of Chemoresistance in Ovarian CancerCompletedNCT02878122
- Mobile Phone Technology to Increase Genetic CounselingCompletedNCT02877862Not applicable
- PET Imaging of Ovarian Carcinoma With 18F-FSPGWithdrawnNCT02872519Early Phase 1
- Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or EndometriumStatus unknownNCT02866370Phase 2
- Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients with Advanced Ovarian Cancer (SUNNY)Active, not recruitingNCT02859038Phase 3
- The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian CancerCompletedNCT02856841
- Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerCompletedNCT02855697Early Phase 1
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT02833506Phase 1
- Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian CancerStatus unknownNCT02822157Phase 2
- Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2
- Improving Quality of Care for Patients With Recurrent Ovarian CancerStatus unknownNCT02809339
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerCompletedNCT02788708Phase 1
- Identification and Referral of Women at Risk for Hereditary Breast/Ovarian CancerCompletedNCT02786147
- Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.CompletedNCT02785731
- Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerActive, not recruitingNCT02785250Phase 1/2
- Physician-Patient Communication and Expectations Regarding Ovarian Cancer PrognosisTerminatedNCT02769546
- Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian CancerActive, not recruitingNCT02758652
- Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian CancerSuspendedNCT02742428Not applicable
- A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian CancerCompletedNCT02737787Phase 1
- Use of Regorafenib in Recurrent Epithelial Ovarian CancerCompletedNCT02736305Phase 2
- Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and TaxaneCompletedNCT02728622Phase 3
- Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With ChemotherapyCompletedNCT02728492Phase 1
- Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective StudyStatus unknownNCT02719041
- Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian CancerStatus unknownNCT02711865
- Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC RiskTerminatedNCT02705924Not applicable
- Treatment for Malignant Ovarian Cancer: Laparoscopy vs LaparotomyStatus unknownNCT02686463Not applicable
- Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian CancerStatus unknownNCT02681432Phase 3
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
- STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian CancerCompletedNCT02676726Not applicable
- Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian CancerCompletedNCT02672098Phase 1
- LCC-CARIS-01: Molecular Profiling in Gynaecological CancerCompletedNCT02668913Not applicable
- Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsCompletedNCT02646319Early Phase 1
- Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
- Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
- HE4 as a Relapse Biomarker in Ovarian CancersCompletedNCT02595281Not applicable
- Total/Subtotal Colectomy in Ovarian CancerStatus unknownNCT02595021Phase 2
- Writing About Experiences With Ovarian CancerCompletedNCT02593422Not applicable
- A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian CancerCompletedNCT02591095Phase 2
- REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological ProgressionCompletedNCT02584465Phase 2
- MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian CancerCompletedNCT02582931Phase 1
- Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic MalignanciesCompletedNCT02578888Not applicable
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2
- Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
- Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian CancerCompletedNCT02567253Phase 2
- Adjuvant Chemotherapy of Three-step Regimen in Ovarian CancerStatus unknownNCT02562365Phase 2
- Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian CancerCompletedNCT02560818Not applicable
- Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.CompletedNCT02560337Phase 2
- Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian CancerStatus unknownNCT02545010Phase 1